title: Developmental therapeutics in acute myelogenous leukemia: are there any new effective cytotoxic chemotherapeutic agents out there?
abstract: Therapies for AML have remained mostly unchanged since the introduction of anthracyline- and cytarabine-based regimens in the 1970s. Though some changes have been made in the dosing of anthracylines, in the choice of consolidation regimens versus allogeneic stem cell transplant, and in supportive care, clinical outcomes remain poor for most patients. As we continue to strive for better treatment options to improve upon outcomes, different agents, both chemotherapeutic and targeted therapies, are being studied. Here we discuss new chemotherapeutic agents that show promise in recent clinical trials and attempt to answer the question if there are any new effective cytotoxic chemotherapy agents out there.
authors: Hollings Cancer Center, Medical University of South Carolina, 96 Jonathan Lucas Street, MSC 635 CSB 903, Charleston, SC 29425, USA. mims@musc.edu
authors: Alice
authors: A
authors: Mims
authors: Robert K
authors: RK
authors: Stuart
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001692:Biological Transport; D002986:Clinical Trials as Topic; D055808:Drug Discovery; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors
references: Cancer. 1997 Dec 1;80(11 Suppl):2205-9
references: 9395035
references: N Engl J Med. 2009 Sep 24;361(13):1235-48
references: 19776405
references: Cancer. 2005 Aug 1;104(3):547-54
references: 15973664
references: Nucleosides Nucleotides Nucleic Acids. 2010 Jun;29(4-6):386-93
references: 20544524
references: Leuk Res. 2010 Jul;34(7):877-82
references: 19962759
references: Br J Haematol. 2012 Sep;158(5):581-8
references: 22702906
references: Leukemia. 2004 May;18(5):989-97
references: 14999298
references: Am J Hematol. 2013 Nov;88(11):961-6
references: 23877926
references: Cancer. 2001 Sep 1;92(5):1059-73
references: 11571716
references: N Engl J Med. 1999 Sep 30;341(14):1051-62
references: 10502596
references: J Clin Oncol. 2011 Mar 10;29(8):979-85
references: 21282541
references: J Clin Oncol. 2007 May 10;25(14):1908-15
references: 17488990
references: Cancer Chemother Rep. 1973 Nov-Dec;57(4):485-8
references: 4586956
references: Leukemia. 2012 Jul;26(7):1686-9
references: 22222600
references: PLoS One. 2010 Apr 15;5(4):e10186
references: 20419121
references: J Clin Oncol. 2012 Jul 10;30(20):2441-8
references: 22508825
references: Blood. 2010 Jan 21;115(3):453-74
references: 19880497
references: J Clin Oncol. 2012 Jul 10;30(20):2492-9
references: 22585697
references: Leuk Res. 2009 Jan;33(1):129-39
references: 18676016
references: J Clin Oncol. 2005 Mar 20;23(9):1969-78
references: 15632409
references: Blood. 2006 May 1;107(9):3481-5
references: 16455952
references: Expert Opin Investig Drugs. 2012 Aug;21(8):1223-33
references: 22724917
references: J Clin Oncol. 2010 Jan 10;28(2):285-91
references: 19933907
references: Cancer Res. 1999 Jun 15;59(12):2944-9
references: 10383159
references: Blood. 2010 Sep 9;116(10):1737-46
references: 20479284
references: Blood. 2002 Dec 15;100(13):4325-36
references: 12393746
references: Lancet Oncol. 2012 Nov;13(11):1096-104
references: 23075701
references: Mol Pharmacol. 2001 Apr;59(4):725-31
references: 11259616
references: N Engl J Med. 2009 Sep 24;361(13):1249-59
references: 19776406
references: Clin Cancer Res. 2010 Apr 1;16(7):2167-75
references: 20233886
references: Cancer. 2012 Sep 15;118(18):4471-7
references: 22282348